CoChat

Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics

Supuran, Claudiu T, Scozzafava, Andrea, Mastrolorenzo, Antonio · 2001 · Expert Opinion on Therapeutic Patents
Cited by 115

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Proteases of the serine-, cysteine- and metallo- type are widely spread in many pathogenic bacteria, where they play critical functions related to colonisation and evasion of host immune defences, acquisition of nutrients for growth and proliferation, facilitation of dissemination, or tissue damage during infection. Since all the antibiotics currently used clinically share a common mechanism of action, i.e., inhibition of bacterial cell wall biosynthesis, resistance to these pharmacological agents represents a serious medical problem, which might be resolved by using a new generation of antibiotics with a different mechanism of action. Bacterial protease inhibitors constitute an interesting possibility, due to the fact that many specific and ubiquitous proteases have recently been characterised in some detail in both Gram-positive and Gram-negative pathogens. Unfortunately, at this moment few potent, specific inhibitors for such bacterial proteases have been reported, except for signal peptidase, clostripain, Clostridium histolyticum collagenase, botulinum neurotoxin and tetanus neurotoxin inhibitors (but such protease inhibitors are not used clinically for the moment). No inhibitors of the critically important and ubiquitous AAA proteases, degP or sortase have been reported, although such compounds would presumably constitute a new class of highly effective antibiotics. On the other hand, several bacterial proteases, such as the Clostridium histolyticum collagenase, or the botulinum neurotoxin A possess therapeutic applications per se for the treatment of some diseases or for the preparation of vaccines. This review presents the state of the art in the design of such enzyme inhibitors with potential therapeutic applications, as well as recent advances in the use of some of these proteases in therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543776.11.2.221

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 115

Metadata

Authors
Supuran, C. T., Scozzafava, A., & Mastrolorenzo, A.
Venue
Expert Opinion on Therapeutic Patents
Published
2001-02
Volume
11
Issue
2
Pages
221-259
ISSN
  • 1354-3776 (ISSN-L)
  • 1744-7674
OpenAlex
W2124438931
Cited by
115
References
8
FWCI
1.65
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.